bevacizumab + sorafenib + cyclophosphamide

Bevacizumab + sorafenib + cyclophosphamide is a combination chemotherapy and targeted therapy regimen being investigated by St. Jude Children's Research Hospital for the treatment of various refractory or recurrent pediatric cancers. The regimen, studied in the Phase I ANGIO1 trial, combines the anti-VEGF monoclonal antibody bevacizumab with the multi-kinase inhibitor sorafenib and low-dose oral cyclophosphamide. This approach aims to synergistically inhibit tumor angiogenesis and growth by targeting the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) pathways while utilizing the cytotoxic and metronomic anti-angiogenic properties of cyclophosphamide. It is primarily indicated for pediatric patients with solid tumors, leukemia, lymphoma, sarcoma, and central nervous system tumors who have failed standard therapies.

Other names

Bevacizumab, Sorafenib, and Cyclophosphamide combinationLow-dose cyclophosphamide combination regimen